HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

490.383

-13.015-2.59%

Number of Gainers:6

Number of Losers:23

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:82.72M

Turnover:2.69B

Market Cap:313.43B

Float Cap:277.25B

Loading ...

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS

What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates

Simply Wall St.

Jacobio Pharmaceuticals Appoints Xiaojie Wang as Vice Chairperson

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

BRII-B (02137) Buys Back 60,000 Shares for HK$60,300 on August 24

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Brii Biosciences Files HKEX Next-Day Disclosure, Lifts Share Capital by 255,793 Shares

和誉-B计划将公司名称更新为“和誉医药有限责任公司”

China's Asymchem H1 Revenue Rises on Strength in Emerging Businesses

China's Shanghai INT Medical Instruments H1 Revenue Jumps on Acquisitions

JACOBIO-B swings to profit with RMB 601 million interim gain

Jacobio Pharmaceuticals Group H1 Net Income Attributable RMB 600.6 Million

THOMSON REUTERS

Jacobio Pharma Appoints Vice Chairperson, Reshuffles Senior Management

Jacobio Pharmaceuticals - Xiaojie Wang Has Been Appointed as the Vice Chairperson

THOMSON REUTERS

Jacobio Pharmaceuticals - Yunyan Hu Tendered Resignation as Executive Vice President of Group

THOMSON REUTERS

China's Peijia Medical H1 Revenue Jumps on Transcatheter Valve Therapeutics Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":490.383,"timestamp":1788250091886,"preClose":503.39795,"halted":0,"volume":82724645,"delay":0,"changeRate":-0.025854,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-13.014954,"latestTime":"09-01 16:00:00","open":503.51608,"high":505.9005,"low":489.5706,"amount":2688849767,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.003099,"increases":6,"decrements":23,"flats":3,"marketCap":313429262448,"floatMarketCap":277247178824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":490.383,"volume":82724645,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.003099,"peRate":127.340212,"marketCap":313429262448,"floatMarketCap":277247178824,"timestamp":1788250091886,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":23,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662026272","title":"RemeGen Swings to Profit in H1 as Revenue Surges Fivefold","url":"https://stock-news.laohu8.com/highlight/detail?id=2662026272","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662026272?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:36","pubTimestamp":1787618181,"startTime":"0","endTime":"0","summary":"RemeGen  posted an attributable profit of 4.66 billion yuan in the first half of 2026, rebounding from an attributable loss of 449.57 billion yuan a year ago.Earnings per share came in at 8.32 yuan, compared with a loss per share of 0.83 yuan a year earlier, according to a Monday filing with the Hong Kong Exchange.Revenue surged year over year to 5.85 billion yuan from 1.09 billion, the biopharmaceutical company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688331","FCA","LU2148510915.USD","BK1574","09995","BK0239","LU1064131003.USD","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1583","LU2488822045.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662025552","title":"Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662025552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662025552?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:30","pubTimestamp":1787617800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUABJPBPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179996720","title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179996720?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:04","pubTimestamp":1787612662,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201482","title":"Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201482","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201482?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611365,"startTime":"0","endTime":"0","summary":"Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesAntengene secured Australian HREC clearance for its Phase 1 ATTRACT trial of ATG-201 in B-cell-mediat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL84Czw1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1574","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201488","title":"Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201488?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611362,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","06996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662202735","title":"What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662202735","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662202735?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:07","pubTimestamp":1787609228,"startTime":"0","endTime":"0","summary":"Today is shaping up negative for Ascentage Pharma Group International ( HKG:6855 ) shareholders, with the analysts...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/what-does-the-future-hold-for-ascentage-pharma-group-interna","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/what-does-the-future-hold-for-ascentage-pharma-group-interna","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827033","title":"Jacobio Pharmaceuticals Appoints Xiaojie Wang as Vice Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827033","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661827033?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:58","pubTimestamp":1787587095,"startTime":"0","endTime":"0","summary":"BRIEF-Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice ChairpersonAug 24 (Reuters)-Jacobio Pharmaceuticals Group Co Ltd1167.HK:XIAOJIE WANG HAS BEEN APPOINTED  AS THE VICE CHAIRPERSONYUNYAN HU TENDERED RESIGNATION AS EXECUTIVE VICE PRESIDENT OF GROUPFurther company coverage:1167.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167515089","title":"mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence","url":"https://stock-news.laohu8.com/highlight/detail?id=1167515089","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167515089?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:52","pubTimestamp":1787583127,"startTime":"0","endTime":"0","summary":"On August 19, Moderna and Merck jointly unveiled positive topline results from the global Phase III INTerpath-001 study evaluating the individualized neoantigen mRNA therapy intismeran autogene...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01952","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113970719","title":"BRII-B (02137) Buys Back 60,000 Shares for HK$60,300 on August 24","url":"https://stock-news.laohu8.com/highlight/detail?id=1113970719","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113970719?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:34","pubTimestamp":1787582054,"startTime":"0","endTime":"0","summary":"BRII-B (02137) has announced that on August 24, 2026, the company spent HK$60,300 to repurchase 60,000 of its own shares.The buyback reflects the company's ongoing capital management strategy, as it...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1587","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","BK1574","LU1093756325.SGD","ORR","BK4533","BK4548","PFS","BK4077","IND","BK4567","IE00B5TLWC47.USD","BK4121","BK4195","BK1161","IE00BFXG0V08.USD","CR","LU0347712357.USD","LU1721428933.USD","BK4161","09969","IE00BYQQ9H92.USD","BK4585","LU2413666426.HKD","MTD","LU1093756168.USD","BK4211","LU2211817866.USD","LU2413666699.HKD","ITP","BK4588","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661747952","title":"Brii Biosciences Files HKEX Next-Day Disclosure, Lifts Share Capital by 255,793 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661747952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661747952?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:18","pubTimestamp":1787581119,"startTime":"0","endTime":"0","summary":"Brii Biosciences files HKEX next-day disclosure, lifts share capital by 255,793 sharesBrii Biosciences filed a next-day disclosure return covering share issuances from option exercises and RSU vesting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL66JBkW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189249598","title":"和誉-B计划将公司名称更新为“和誉医药有限责任公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=1189249598","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189249598?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:35","pubTimestamp":1787578523,"startTime":"0","endTime":"0","summary":"和誉-B（02256）近日发布公告，公司董事会已提议对现有名称体系进行调整。根据公告内容，和誉开曼有限责任公司的英文名称将由“Abbisko Cayman Limited”变更为“Abbisko Medicine Co., Ltd.”，同时其中文双重外文名称也将从“和誉开曼有限责任公司”同步更新为“和誉医药有限责任公司”。此次名称变更提案旨在进一步优化公司品牌形象，并更好地反映其业务发展定位。目前该建议已正式提交，尚待相关程序批准后生效。市场投资者可关注后续公告以获取最新进展。","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256","IE00B543WZ88.USD","LU2778985437.USD","BK1574","IE00B5MMRT66.SGD","159938","BK1515","LU2476274308.USD","BK1161","09939","IE00BPRC5H50.USD","LU2488822045.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271443","title":"China's Asymchem H1 Revenue Rises on Strength in Emerging Businesses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271443","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271443?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:32","pubTimestamp":1787578375,"startTime":"0","endTime":"0","summary":"China's Asymchem H1 revenue rises on strength in emerging businessesOverviewChina CDMO provider's H1 revenue rose 13% yr/yr, net profit fell 16%Company attributed profit decline mainly to exchange rat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688428","002821","BK1574","BK0132","LU1328615791.USD","01167","BK1191","06821","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271618","title":"China's Shanghai INT Medical Instruments H1 Revenue Jumps on Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271618","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271618?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:23","pubTimestamp":1787577791,"startTime":"0","endTime":"0","summary":"China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitionsOverviewChina medical device maker's H1 revenue rose 29% yr/yr, driven by acquisitions and higher device salesProfit for the pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1222","BK0239","01501","688428","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195855780","title":"JACOBIO-B swings to profit with RMB 601 million interim gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1195855780","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195855780?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:52","pubTimestamp":1787575944,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) has released its interim results for the six months ended June 30, 2026, reporting revenue of RMB 731 million, a substantial increase of 1,500.5% year-on-year. The company recorded...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279584","title":"Jacobio Pharmaceuticals Group H1 Net Income Attributable RMB 600.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279584?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:42","pubTimestamp":1787575346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nPLX3MQ6Q6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661795872","title":"Jacobio Pharma Appoints Vice Chairperson, Reshuffles Senior Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2661795872","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661795872?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:42","pubTimestamp":1787575346,"startTime":"0","endTime":"0","summary":"Jacobio Pharma appoints vice chairperson, reshuffles senior managementJacobio announced board-level and senior management changes alongside its interim results for the six months ended June 30, 2026.T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6Rh8LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661793042","title":"Jacobio Pharmaceuticals - Xiaojie Wang Has Been Appointed as the Vice Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2661793042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661793042?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:41","pubTimestamp":1787575299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279301","title":"Jacobio Pharmaceuticals - Yunyan Hu Tendered Resignation as Executive Vice President of Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279301?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:41","pubTimestamp":1787575299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L06Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661919276","title":"China's Peijia Medical H1 Revenue Jumps on Transcatheter Valve Therapeutics Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661919276","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661919276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:14","pubTimestamp":1787573695,"startTime":"0","endTime":"0","summary":"China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growthOverviewChina medical device maker's interim revenue grew 20.1% yr/yr, reaching RMB424.5 mlnCompany achieved first-eve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0239","BK1574","BK1100","688428","09996"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":11,"totalSize":379,"code":"91000000","status":"200"}]}}